This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Anticoagulants Industry

Anticoagulant Therapy in IPF: Reduces Mortality Risk II-5

Anticoagulants to Lose UA/AMI Markets to Antiplatelets II-5

An Opportunity to Grow Further II-5

Warfarin & Heparins: The Former Market Leaders II-5

Generics Drugs Prevail in the Anticoagulant Market II-6

Concern Over Underutilization of Warfarin II-6

Novel Oral Anticoagulants to Turbo-Charge Market Growth II-7

Hurdles Exist for New Oral Agents II-7

The Merits and Demerits of New Age Anticoagulants II-7

Lack of Adequate Trials Mar Pediatric Anticoagulants Market II-8

Improved Anticoagulant Agents for Children Group II-8

Growing Demand for Self-Testing II-8

LMWHs Ease Outpatient Management II-8

Novel Heparins Enhance Market Potential II-9

A Focus on Failed or Withdrawn Agents in Recent Past II-9

Idraparinux and Idrabiotaparinux Sodium - Sanofi's

Discontinued Agents II-9

Lack of Statistical Significance Leads to Culmination of

Tecarfarin's Development II-10

Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma II-10



Traditional Oral Anticoagulants II-11

Warfarin II-11

Advantages and Alternatives II-11

Side Effects II-11

Limitations II-12

Coumadin - The Branded Warfarin II-12

Novel Oral Anticoagulants II-12

Dabigatran Etexilate (Pradaxa) II-12

Table 1: Pradaxa and Warfarin - A Comparative Study II-13

Approved Indications for Pradaxa in Select Regions II-13

Rivaroxaban (Xarelto) II-13

Approved Indications for Xarelto in Select Regions II-14

Xarelto Patent Expiration in Various Regions II-14

Apixaban (Eliquis) II-15

Betrixaban II-15

Comparison of Select Approved and Pipeline Anticoagulant

Agents in a Nutshell II-15

Market Dynamics II-16

New Oral Drugs More Efficacious In Reducing Stroke II-16

New Generation Anticoagulants Enter the Market, Warfarin

Comes Under Pressure II-16

Oral Anticoagulants Market to Witness Intense Competition II-16

Pradaxa- A High Potential Replacement to Warfarin II-17

Packaging May Hurt Pradaxa's Prospects II-17

New Oral Drugs in Various Indications II-17

Emerging Targets in the Anticoagulation Space II-18

Daiichi Sankyo Upbeat on Prospects of Edoxaban II-18

ELIQUIS' FDA Approval Faces Further Delays II-19

2 of 15

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,866.83 +88.68 0.50%
S&P 500 2,074.82 +13.59 0.66%
NASDAQ 4,775.6470 +27.2510 0.57%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs